课题基金 / 基金详情

UCSD Cancer Center Training Program in Drug Development

UCSD Cancer Center Training Program in Drug Development
加州大学圣地亚哥分校癌症中心药物开发培训项目
批准号:
7446128
负责人:
STEPHEN B HOWELL
金额:
$43.64万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2011-06-30

项目摘要

项目成果

STEPHEN B HOWELL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请者提供):这是一个新的为期两年的博士后培训计划的申请,在癌症研究,更具体地说,在丽贝卡和约翰摩尔斯加州大学圣迭戈分校癌症中心,NCI指定的综合癌症中心的开发。这16名教职员工来自医学院和斯卡格斯加州大学圣迭戈分校的药学和药学学院的医学系、病理学系、外科系和药理学系。每位教师导师都是癌症中心的参与成员,对癌症或与癌症相关的研究资金进行了同行审查。这项计划很好地融入了癌症中心和加州大学圣迭戈分校的其他癌症相关活动。目标是在这个为期两年的项目中招聘和保留8名医学博士和博士科学家,从事学术癌症研究,重点是针对发育疗法的转化性研究。受训人员将被要求通过医学院管理和NIH资助的CREST计划、由该培训计划协调的讲座系列、癌症中心和部门研讨会、受训人员的期刊俱乐部以及定期安排的会议来参加课程,以扩大他们的癌症研究培训和视角。所有参与的教职员工都在进行翻译研究,他们之所以被选中,是因为他们对新的癌症疗法感兴趣。该计划将使用相关的NCI赠款项目,包括针对癌症差异的癌症中心/少数族裔机构合作计划的U56规划拨款,以及正在进行的学术公私合作计划(AP4)的U54拨款申请。它还将采用最近开放的摩尔癌症中心大楼,这是一座27万平方英尺的最先进的多用途建筑,结合了临床护理与基础和预防研究。制定了确保所有受训人员接受负责任的研究和科学诚信原则的适当指导的方法。 对与癌症相关的学术研究感兴趣,并致力于至少两年的研究培训的MD研究员将从加州大学圣迭戈分校的血液学/肿瘤学、外科和放射学奖学金项目以及全国范围内招募。博士申请者来自加州大学圣迭戈分校和其他具有生物学、生物化学、化学和分子或细胞生物学背景的研究型大学,他们选择发展与开发新的癌症疗法相关的技能。将通过我们的伙伴关系赠款和其他工具做出特别努力,招募和留住该方案的特殊少数族裔和女性候选人。
英文摘要
DESCRIPTION (provided by applicant): This is an application for a new two-year postdoctoral training program in cancer research and more specifically in the development of new cancer agents, at the Rebecca and John Moores UCSD Cancer Center, an NCI designated comprehensive cancer center. The 16 faculty members come from the departments of Medicine, Pathology, Surgery, and Pharmacology within the medical school and the Skaggs UCSD School of Pharmacy and Pharmaceutical Sciences. Each faculty mentor is a participating member of the Cancer Center, having peer reviewed cancer or cancer-related research funding. This program is well integrated into the other cancer related activities of the Caner Center and of UCSD. The goal is to recruit and maintain 8 MD and PhD scientists in this two year program for careers in academic cancer research, with an emphasis on translational research targeted at developmental therapeutics. Trainees will be required to take courses through the medical school managed and NIH funded CREST program; a lecture series coordinated by this training program, Cancer Center and departmental seminars, a journal club for the trainees, and regularly scheduled conferences to expand their cancer research training and perspectives. All of the participating faculty are conducting translational research and have been selected because of their interest in new cancer therapeutics. This program will employ related NCI grant projects including a U56 planning grant for a cancer center/minority institution partnership program in cancer disparities, as well as a pending U54 grant application for an Academic Public, Private Partnership Program (AP4). It will also employ the recently opened Moores Cancer Center building, a 270,000 sf state of the art multi-use structure combining clinical care with basic and prevention research. Methods are in place to ensure that all trainees are properly instructed in the principles of responsible conduct of research and scientific integrity. MD fellows who are interested in academic research related to cancer, and committed to at least two years of research training will be recruited from the Hematology/Oncology, Surgery and Radiology fellowship programs here at UCSD as well as nationwide. PhD applicants come to us from within UCSD and from other research universities with strong backgrounds in biology, biochemistry, chemistry and molecular or cellular biology, and choose to develop their skills related to developing new cancer therapeutics. Special efforts will be made through our partnership grant and other vehicles to recruit and retain exceptional minority and women candidates to the program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vivo detection and genome-wide location analysis of DNA-adducts
Control of the cellular pharmacology of the platinum-containing drugs by CTR1
Control of the cellular pharmacology of the platinum-containing drugs by CTR1
Control of the cellular pharmacology of the platinum-containing drugs by CTR1
海外基金